TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07572812: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of UX-GIP001 (Human GABAergic Interneuron Progenitor Cells Injection) in the Treatment of Drug-Resistant Unilateral Mesial Temporal

Sponsor: Shanghai UniXell Biotechnology Co., Ltd · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,303,184

Rescue Site Savings

+$3,509,072

Unlock Full NCT07572812 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07572812 Rescue Dossier →